CELLPOINT-DIGITAL
10.11.2021 14:23:03 CET | Business Wire | Press release
CellPoint Digital, a fintech leader in payment orchestration, today announces the next leg of its partnership with Cebu Pacific, the largest airline in the Philippines.
Cebu Pacific is one of the most successful low-cost airlines in the world, having flown over 22 million passengers to over 60 destinations in 2019, with 70% of these bookings being made directly via the carrier’s digital channels.
Following the successful implementation of CellPoint Digital’s cutting-edge Payment Orchestration Platform, Velocity, across all of Cebu Pacific’s digital channels last year, the airline has now implemented new alternative payment methods to provide more flexible options to their customer’s payment experience. Thanks to the PSP/acquirer agnostic Velocity platform, Cebu Pacific customers will now have access to the following popular payment methods: GCash , GrabPay and PayMaya .
The new alternative payment methods boast wide-ranging end-user benefits, including enabling split payments between travel fund vouchers and cash, and converting local currencies in real-time. For the airline itself, providing more payment methods should increase revenues, and by optimising card payment processing across multiple acquirers, they will be able to do real-time transaction monitoring – by market, and by payment method – all delivered conveniently in one place.
The intelligent routing module already dynamically optimises the routing of each transaction made via a bespoke network of acquiring banks, thereby maximising acceptance rates and lowering transaction costs.
Candice Iyog, Vice-president for Marketing and Customer Experience at Cebu Pacific added: “Our partnership with CellPoint Digital continues to go from strength to strength. As the world begins to open back up and consumers are more used to using flexible digital payment methods than ever before, we’re proud to be able to offer our customers a frictionless customer experience at checkout by giving them the payment methods they most want to use.”
Commenting on the announcement Kristian Gjerding, CEO of CellPoint Digital commented: “We’re delighted to announce this evolution in our partnership with Cebu Pacific. Airlines have, by necessity, some of the most complex payment ecosystems of modern merchants, and an equally diverse customer base to match. By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we have simplified the payment process for Cebu while bolstering its offering with popular alternative payment methods for its customers.”
The news comes as the APAC airline sector gears up to take off again following the disruption caused by the COVID-19 pandemic, with 77% of APAC airline customers ready to travel as soon as restrictions fully ease. Via its access to CellPoint Digital’s growing ecosystem, Cebu Pacific is ready to maximise the payments journey for APAC travellers with payment methods covering over 40 local and global cards, and over 350 alternative payment methods.
The future is promising for the partnership as the two companies work towards introducing more new features such as stored cards and other popular APMs, while also empowering Cebu’s B2B offering with more payment capabilities.
To find out more about CellPoint Digital, visit: https://cellpointdigital.com/
To find out more about Cebu Pacific, visit: https://www.cebupacificair.com/
ENDS
About CellPoint Digital
CellPoint Digital makes payments easier™ for airlines, travel companies and other international merchants and their customers.
CellPoint Digital is a fintech leader in payment orchestration. Our main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment eco-system across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rate and minimise payment costs. CellPoint Digital also provides an end-to-end digital commerce platform to airlines that masters the entire customer sales cycle and maximises the conversion rate.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About Cebu Pacific
Cebu Pacific Air is one of the most successful low-cost carriers in the world and a pioneer of the “low fare, great value” strategy. Cebu started operations in 1996 and has since carried over 150 million passengers. Cebu is the largest carrier in the Philippine air transportation industry, offering low-cost services to more destinations and routes with higher flight frequency within the Philippines than any other airline. It began long-haul services in 2013. Cebu currently offers flights to 37 Philippine and 26 international destinations, spanning Asia, Australia, and the Middle East. Cebu offers a uniquely upbeat flying experience, offering fun in the skies with our “Fun Games” on board. Visit https://cebupacificaircorporate.com/Pages/company-info.aspx to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005810/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom